Choice of agent for peripheral thrombolysis

Area of Science:

• Vascular Surgery
• Pharmacology
• Emergency Medicine

Background:

• Peripheral thrombolysis is crucial for limb salvage in acute limb-threatening ischemia.
• Tissue plasminogen activator (tPA) is suggested as a superior alternative to streptokinase.
• Comparative efficacy and safety data are essential for clinical decision-making.

Purpose of the Study:

• To compare the effectiveness and safety of tPA versus streptokinase for peripheral thrombolysis.
• To evaluate limb salvage rates and complication profiles associated with each thrombolytic agent.
• To determine if the higher cost of tPA is justified by improved outcomes.

Main Methods:

• Retrospective comparison of 23 patients treated with tPA (0.5 mg/h) and 20 patients treated with streptokinase (5,000-10,000 units/h).
• Assessment of complete and partial lysis rates.
• Evaluation of limb salvage rates and complication incidence.

Main Results:

• No significant differences in complete or partial lysis rates between tPA (61%) and streptokinase (65%).
• Similar limb salvage rates were observed: 65% for tPA versus 55% for streptokinase.
• Complication rates were comparable between the two treatment groups.

Conclusions:

• tPA did not demonstrate superior efficacy or safety compared to streptokinase in this cohort of peripheral thrombolysis.
• The increased cost of tPA was not supported by evidence of improved outcomes in this study.
• Further research may be needed to identify specific patient subgroups who might benefit more from tPA.